Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;25(1):199-206.
doi: 10.1007/s12094-022-02923-7. Epub 2022 Sep 6.

Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study

Milica Stefanovic  1   2 , Gemma Calvet  3 , Héctor Pérez-Montero  3   4 , Anna Esteve  5 , Montse Ventura Bujalance  3   4 , Arturo Navarro-Martín  3   4   6 , Maria Dolores Arnaiz Fernández  3 , Ferran Ferrer González  3   4   6 , Susanna Marin Borras  3   6 , Alicia Lozano Borbalas  3 , Miriam Nuñez Fernandez  3   4 , Miquel Macia Garau  3   4   6 , Anna Lucas Calduch  3   4 , Ferran Guedea Edo  3   4   6
Affiliations

Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study

Milica Stefanovic et al. Clin Transl Oncol. 2023 Jan.

Abstract

Purpose: Stereotactic body radiation therapy (SBRT) is a treatment modality with curative intent for oligometastatic cancer patients, commonly defined by a low-burden metastatic disease with 1-5 systemic metastases. Better knowledge of the clinical profile and prognostic factors in oligometastatic cancer patients could help to improve the selection of candidates who may obtain most benefits from SBRT. The objective of this study was to describe the clinical data and outcome in term of overall survival (OS) of patients with oligometastatic disease treated with SBRT over a 6-year period.

Methods: From 2013 to 2018, 284 solid tumor cancer patients with 1-5 oligometastases underwent SBRT at a large university-affiliated oncological center in Barcelona, Spain. Variables related to the patient profile, tumor, oligometastatic disease, and treatment were evaluated.

Results: A total of 327 metastatic tumors were treated with SBRT. In 65.5% of cases, metachronous tumors were diagnosed at least 1 year after diagnosis of the primary tumor. The median age of the patients was 73.9 years and 66.5% were males. The median follow-up was 37.5 months. The most common primary tumors were lung and colorectal cancer, with lung and bone as the most commonly treated metastatic sites. Ninety-three percent of patients showed a Karnofsky score (KPS) between 80 and 100. Adenocarcinoma was the most common histological type. The median overall survival was 53.4 months, with 1-, 2- and 5-year survival rates of 90.5%, 73.9% and 43.4%, respectively. Overall survival rates of breast (67.6 months, 95% CI 56.4-78.9), urological (63.3 months, 95% CI 55.8-70.8), and colorectal (50.8 months, 95% CI 44.2-57.4) tumors were higher as compared with other malignancies (20 months, 95% CI 11.2-28.8 months) (p < 0.001). Patients with Karnofsky score (KPS) of 90 and 100 showed a significantly better survival than those with impaired performance status (p = 0.001).

Conclusion: SBRT appears to be well tolerated and safe approach in oligometastatic patients. Patients with good performance status and with primary breast, urological and colorectal cancer have higher OS compared with other malignancies. More studies are necessary to evaluate the prognostic factors in oligometastatic disease (OMD) in order to select patients who could benefit more from this therapeutic approach.

Keywords: Oligometastases; Oligometastatic disease; Risk factors; Stereotactic body radiation therapy; Survival.

PubMed Disclaimer

References

    1. Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6(11):8491–524. https://doi.org/10.18632/oncotarget.3455 . - DOI
    1. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28. https://doi.org/10.1016/S1470-2045(19)30718-1 . - DOI
    1. Ahmed KA, Torres-Roca JF. Stereotactic body radiotherapy in the management of oligometastatic disease. Cancer Control. 2016;23(1):21–9. https://doi.org/10.1177/107327481602300105 . - DOI
    1. Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward WA. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66. https://doi.org/10.1016/j.radonc.2020.04.003 . - DOI
    1. Zayed S, Correa RJM, Palma DA. Radiation in the treatment of oligometastatic and oligoprogressive disease: rationale, recent data, and research questions. Cancer J. 2020;26(2):156–65. https://doi.org/10.1097/PPO.0000000000000436 . - DOI

LinkOut - more resources